Abstract: The invention relates to complexing agents of formula (I): wherein Chrom1, Chrom2 and Chrom3 are as defined in the description. The invention also relates to lanthanide complexes obtained from these complexing agents.

Abstract: The invention relates to a compound of formula (I) wherein R1; R2, R3 and R4 are as defined in the description. The invention also relates to europium (III) complexes obtained from a compound of formula (I), or from a complexing agent including said compound, and to the use of such complexes to label organic or biological molecules.

Abstract: The invention relates to complexing agents of formula (I) in which A1, A2, A3 and R1 are as defined in the description. The invention also relates to lanthanide complexes obtained from said complexing agents. The invention can be used for marking biological molecules.

Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.

Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.

Abstract: The invention relates to a method for detecting the binding of an antibody to an Fc receptor present on the surface of a cell as well as to a method for determining the level of glycosylation of an antibody. The invention also relates to a reagent kit for carrying out these methods.

Abstract: The present invention concerns complexing agents of formula (I) in which a, b, c, chrom1, chrom2, chrom3, R3, R4 and R5 are as defined in the description. The invention also concerns lanthanide complexes comprising said complexing agents, as well as a method for synthesizing said agents.

Abstract: The invention relates to complexing agents of formula (I): in which A, chrom1, chrom2 and chrom3 are as defined in the description. The invention also relates to the lanthanide complexes obtained from these complexing agents.

Abstract: The subject matter of the invention is a method for measuring the luminescence of a long-life fluorescent compound present in a measuring medium, said medium containing a biological sample, characterized in that it comprises the following steps: a) introduction of a long-life fluorescent compound into the measuring medium, b) introduction, into the measuring medium, of a fluorescent marking agent, the absorption spectrum of which allows the excitation thereof at the same wavelength as that used to excite the long-life fluorescent compound, wherein said emission spectrum allows the measurement of the luminescence thereof at the same wavelength as that used to measure the luminescence of the long-life fluorescent compound, c) excitation of the measuring medium with a wavelength corresponding to an absorption peak of the long-life fluorescent compound, d) measurement of the luminescence emitted by the measuring medium immediately after excitation of said medium, mainly corresponding to the luminescence of the

Abstract: The invention relates to a method for detecting the binding of an antibody to an Fc receptor present on the surface of a cell as well as to a method for determining the level of glycosylation of an antibody. The invention also relates to a reagent kit for carrying out these methods.

Abstract: The present invention concerns complexing agents of formula (I) in which a, b, c, chrom1, chrom2, chrom3, R3, R4 and R5 are as defined in the description. The invention also concerns lanthanide complexes comprising said complexing agents, as well as a method for synthesizing said agents.

Abstract: The invention relates to a method for quantifying a protein of interest expressed at the surface of a cell or else present in a tissue sample, said method comprising the use of two ligands capable of binding specifically to a domain of said protein.